Kinapse Blog
Read our latest insights into the Life Sciences industry.
Adapt or die: The risks of not being patient centric
Threatened by innovative biotech organisations, Pharma companies need to accelerate their patient centricity initiatives or risk falling behind.
Kinapse features in the International Track 200 for second year running
For the second consecutive year, Kinapse has ranked in the top 200 mid-market private companies with the fastest-growing overseas sales, according to the Sunday Times HSBC International Track 200.
The Regulatory Times June 2018
Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read June's edition from Kinapse.
Kinapse goes from strength to strength
The life sciences consultancy has seen another year of double-digit growth, major client wins, new hires and promotions.
The applications of blockchain in the Pharmaceutical industry
In the first of a four part blog series, we outline what blockchain is, and what applications it could present to the Pharmaceutical industry.
Drug pricing affordability: how to clear the 5th Market Access hurdle
Fuelled by media scrutiny, drug affordability is becoming an increasingly powerful influence in market access decisions today. Learn how to overcome it.
Patient Centricity: how digital is giving patients control of managing their care
Lean Biotechs and patients themselves are using new technology to revolutionise the patient experience. In order to keep up, Pharma needs to significantly accelerate and strengthen its value proposition in the digital space.
The Regulatory Times April 2018
Your monthly compilation of regulatory news from around the globe. Follow the link to read March's edition from Kinapse.
Health Canada aligns with EMA on public clinical trial reporting – with a few key differences
Health Canada have drafted a guidance document relating to the planned public release of clinical trial documents, broadly in line with EMA Policy 0070. What are the key differences? How should your organisation prepare?
Creating plain language summaries for clinical studies
Plain language summaries of clinical study reports must be understood by lay readers and clinical experts. How should organisations strike the balance?
Community spotlight: Vivek Tomar
We would like to take the opportunity to highlight the inspiring work of one of our employees, Vivek Tomar.
The Regulatory Times March 2018
Your monthly compilation of regulatory news from around the globe. Follow the link to read March's edition from Kinapse.
Why US organisations need to prepare for an equivalent to EMA policy 0070
A recently announced FDA pilot program suggests that the agency is taking steps towards implementing an equivalent to the EMA's policy 0070. US-based organisations should act now to prepare.
Kinapse signs the Armed Forces Covenant
On 20th March 2018, Kinapse was proud to sign the Armed Forces Covenant. We were honoured to welcome Major General Chris Tickell CBE to our Wimbledon offices to celebrate with us and to countersign our Covenant on behalf of The Ministry of Defence.
Artificial intelligence in the Life Sciences industry
With the Life Sciences industry playing catch-up on AI, how are industry leaders narrowing the gap? John Cogan, Head of innovation, shares his views.
A best practice approach for achieving EMA policy 0070 compliance
Want to learn the most efficient way to run a clinical trial anonymisation project? Read our step-by-step guide to achieving EMA policy 0070 compliance.